Bicalutamide – Non-Steroidal Antiandrogen Therapy for Prostate Cancer

Bicalutamide is an oral, non-steroidal antiandrogen of first choice belonging to the phenoxybenzamide derivatives, engineered for the highly selective hormonal therapy of advanced prostate cancer. The mechanism of action of bicalutamide involves competitive binding to androgen receptors (AR) on the surface and within malignant cells. By occupying the binding domain, the drug effectively blocks receptor stimulation by endogenous androgens—namely testosterone and dihydrotestosterone (DHT). This halts the translocation of the receptor complex into the cell nucleus, suppresses the transcription of androgen-dependent target genes, and completely compromises mitotic signaling pathways. Consequently, this induces widespread apoptosis and involution of hormone-sensitive malignant prostate clones. Bicalutamide is a pure antiandrogen and, unlike steroidal alternatives, lacks any inherent internal hormonal (progestational, estrogenic, or glucocorticoid) activity.

The clinical uniqueness of bicalutamide lies in its ability to deliver a profound and sustained peripheral receptor blockade while maintaining a stable therapeutic plateau, making it suitable for both monotherapy and within maximal androgen blockade (MAB) combined with surgical castration or gonadotropin-releasing hormone (GnRH) analogues. The drug undergoes slow but complete absorption within the gastrointestinal tract following oral administration. Downstream pharmacodynamics are determined by optical isomerism: antiandrogen activity resides almost exclusively in the (R)-enantiomer, which features a prolonged elimination half-life from plasma (approximately 7 days). The drug is extensively metabolized in the liver via oxidation and subsequent glucuronidation mediated by cytochrome P450 isoenzymes. Metabolites are excreted in roughly equal proportions via the kidneys in the urine and through the intestines in the feces.

The drug is administered orally. Initiating therapy requires prior histological verification of prostate adenocarcinoma and baseline assessment of prostate-specific antigen (PSA) levels. Continuous laboratory monitoring of hepatic function parameters is mandatory throughout long-term treatment due to risks of delayed hepatotoxicity.

Wikipedia page
Bicalutamide

Indications

Bicalutamide is indicated as a systemic hormonal therapy for adult patients with the following malignant oncological condition:

  • Advanced Prostate Cancer: treatment of locally advanced prostate cancer (as monotherapy or adjuvant therapy following radical prostatectomy or radiotherapy) or metastatic prostate cancer as part of combined maximal androgen blockade in conjunction with GnRH analogue therapy or surgical castration.

Dosage and administration

The dosing regimen of bicalutamide is continuous and structured for long-term daily administration, depending directly on the clinical stage of the disease and the selected therapeutic protocol.

  • Standard Dose in Combination Therapy: the recommended dose for metastatic cancer within MAB (co-administered with a GnRH analogue) is 50 mg (one tablet) taken orally once daily. Treatment should be initiated concurrently with the GnRH analogue regimen.
  • Standard Dose in Monotherapy: the recommended therapeutic dose for the management of locally advanced prostate cancer without metastases is 150 mg (three 50 mg tablets or one specialized 150 mg tablet) taken orally once daily.
  • Schedule and Duration: the drug is taken daily without planned treatment breaks. Therapy must be maintained long-term (for months or years) as long as an objective clinical response (monitored by PSA levels) is sustained or until clear disease progression occurs.
  • Administration Method: tablets must be swallowed whole at approximately the same time each day, with or without food. Tablets must not be broken or chewed, and should be administered with a sufficient volume of water.
  • Missed Dose: if a scheduled dose is missed, an additional tablet should not be taken later that day, nor should the dose be doubled the following day. The patient must simply resume treatment with the next planned dose according to their regular schedule.

The use of bicalutamide is restricted by specific gender boundaries, risks of severe hepatic injury, and drug-to-drug incompatibility, and is contraindicated in the following conditions:

  • Hypersensitivity: documented history of allergic reactions, anaphylactic manifestations, or individual hypersensitivity to bicalutamide or any inactive formulation excipients.
  • Use in Women and Children: the drug is strictly contraindicated in women (including pregnant or lactating mothers due to pronounced teratogenic and fetotoxic potential) and pediatric patients.
  • Severe Hepatic Impairment: pre-existing severe hepatic insufficiency (Child-Pugh Class C) due to delayed drug clearance leading to a high risk of critical systemic accumulation.
  • Drug Interactions: concomitant administration with cisapride, astemizole, or terfenadine is strictly contraindicated due to elevated risks of QTc interval prolongation and severe arrhythmias.

The side effects of bicalutamide are driven by the pharmacological blockade of androgen receptors in healthy tissues and its specific hepatic metabolism clearance pathways:

  • Endocrine Disorders: very frequently presents as hot flashes (vasomotor symptoms), pronounced breast tenderness, gynecomastia (breast enlargement in men, particularly at the 150 mg dose), decreased libido, and erectile dysfunction.
  • Hepatobiliary System: transient elevations in liver transaminases (ALT, AST), hyperbilirubinemia; rare instances of severe hepatotoxic reactions, including cholestasis, jaundice, and hepatic failure, have been reported.
  • Gastrointestinal Tract: moderate nausea, vomiting, abdominal pain, diarrhea, dyspepsia or persistent constipation, and pronounced decreased appetite (anorexia).
  • Systemic Manifestations: increased fatigue, marked asthenia, generalized musculoskeletal pain, peripheral edema of the lower extremities, xerosis (dry skin), and skin rash.
  • Cardiovascular System: mild exertional dyspnea, fluid retention, and elevated risks of developing heart failure or angina pectoris during prolonged usage.

Frequently Asked Questions

Bicalutamide is a non-steroidal antiandrogen therapy specifically engineered for the treatment of prostate cancer. It operates through the competitive inhibition of androgen receptors within prostatic tissues. By binding to these receptors, bicalutamide prevents endogenous male hormones (testosterone and dihydrotestosterone) from accessing them and driving malignant cellular division. Consequently, the tumor is deprived of necessary hormonal growth signals, leading to regression.
Bicalutamide is indicated for the management of advanced or metastatic prostate cancer. It can be administered either as a monotherapy or as part of a combined androgen blockade (CAB) regimen alongside surgical castration or gonadotropin-releasing hormone (GnRH) analogs. Additionally, it is frequently introduced at the initiation of GnRH analog therapy to mitigate the tumor "flare" phenomenon, which is a transient surge in testosterone that can worsen symptoms.
Bicalutamide is administered orally as a single tablet (the standard daily dose is either 50 mg or 150 mg, depending on the clinical protocol) once daily. The medication should be taken at a consistent time each day. Food intake does not alter the bioavailability or therapeutic response of bicalutamide; therefore, tablets may be taken before, during, or after meals, and must be swallowed whole with water.
Bicalutamide is extensively metabolized by the liver, and its administration is associated with alterations in hepatic function, such as significant elevations in transaminases (ALT and AST). Rare but severe cases of hepatotoxicity and jaundice have been reported. Your physician will request regular liver function tests, particularly during the first 6 months of treatment. If critical hepatic impairment is detected, bicalutamide therapy must be discontinued immediately.
The systematic blockade of androgen receptors can precipitate several endocrine-related adverse effects. The most frequent clinical manifestations include gynecomastia (breast tissue swelling and tenderness) and hot flashes. Patients may also experience a reduction in libido, erectile dysfunction, increased fatigue, and dry skin. Widespread chest tenderness or any debilitating hormonal symptoms should be reported to the managing oncologist to discuss appropriate supportive care.

List of medicines by active substance

-17%
Calupros
View
Everest

Calupros

Bicalutamide
50 mg 30 tablets
3353₴ 4023₴
✅ All products loaded (1)
Unifarm

Unifarm app

Safari → Share → Add to Home Screen Firefox: menu ⋮ → Install or Add to Home screen. If missing, open the site in Chrome. Chrome: menu ⋮ → Install app or Add to Home screen.

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00